RENAL GRAND ROUNDS. Vitamin D- Beyond the bone. Dr Krishna Pakkivenkata. 9 th April 2010.
|
|
- Milton Bond
- 6 years ago
- Views:
Transcription
1 RENAL GRAND ROUNDS Vitamin D- Beyond the bone Dr Krishna Pakkivenkata. 9 th April 2010.
2 Brief history Secosteroid s-exposure to sunlight prevented rickets structure of Vit D was discovered s-metabolic pathway of Vit D.
3 Synthesis and Metabolism of Vitamin D in the Regulation of Calcium, Phosphorus, and Bone Metabolism Holick M. N Engl J Med 2007;357:
4 Brief history s-vit D receptor presence was discovered in other tissues VDR was cloned.
5 Meta-analysis of data on all-cause mortality in 18 randomized controlled trials with vitamin D Autier, P. et al. Arch Intern Med 2007;167:
6 Rate Ratios of All-Cause and CVD Mortality by 25(OH)D Quartiles in Participants of NHANES IIIa Melamed, M. L. et al. Arch Intern Med 2008;168:
7 Restricted cubic spline analysis Melamed, M. L. et al. Arch Intern Med 2008;168:
8 Vitamin D receptor UVR Skin 7 dehydroxycholesterol Vitamin D 3 1α hydroxylase Kidney Liver 1,25(OH) 2 D 3 25(OH)D 3 Prostate 25(OH)D 3 Other tissues 1,25(OH) 2 D 3 VDR Retinoid X receptor Target cell nucleus VDRE Transcription
9 Vitamin D Receptor Gene Chr 12q13 9 exons, alternatively spliced promoter region Binding domains: DNA binding domain binds VDRE Ligand binding domain 1,25(OH) 2 Vit D 5 3 1f 1e 1a 1d 1b 1c UTR Promoter region DNA Binding domain Ligand Binding domain
10 Single Nucleotide Polymorphism in the VDR gene 5 3 1f 1e 1a 1d 1b 1c UTR Cdx-2 GATA Fok1 Taq Apa1 Poly A Human VDR >470 reported SNPs Many have low allele frequencies and not suited for genetic studies
11 Target organs for vitamin D. Valdivielso, J. M. et al. Am J Physiol Renal Physiol 297: F1502-F ; doi: /ajprenal Copyright 2009 American Physiological Society
12 Pleotropic effects OF Vit D Cancer. Osteoarthritis. Depression. Epilepsy. Polycystic Ovaries. Musculoskeletal Pain. Autoimmune Disease. Multiple Sclerosis. Falls in the Elderly. Pregnancy and Lactation.
13 Pleotropic effects of vitamin D Vit D and renoprotective and immunomodulatory effects. Vit D- Cardiometabolic actions.
14 Vit D and renoprotective effects Vit D and proteinuria. Vit D and RAS. Vit D and anti inflammatory effect. Vit D and immunomodulatory effects.
15 Overview of the potential renoprotective effects of active vitamin D in the damaged kidney Doorenbos, C. R. C. et al. (2009) Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism Nat. Rev. Nephrol. doi: /nrneph
16 Hypertension Aug;52(2): Randomized double blind pilot study. Included 24 CKD patients - >18yrs,GFR >30, Taking ACE or ARB. Divided into 3 groups Randomly receiving placebo, 1mcg or 2mcg paricalcitol for 1month. Primary endpoint- evaluate for endothelial function and inflammation. Secondary end points-hemodynamic effects by measuring BP,GFR and urinary albumin. Being a small study power calculations were not performed to determine minimal sample size.
17
18 Placebo-1.5 times the baseline CPR. 1mcg- 0.8 times. 2mcg- 0.5 times. Hypertension Aug;52(2):249-55
19 > 35% <48% <46% Hypertension Aug;52(2):249-55
20 Summary Paricalcitrol may reduce albuminuria and inflammation in CKD patients. No significant effect on endothelial function, GFR, or BP.
21 Kidney International (2006) 70, VDR + vs VDR MICE. Substances-1,25 (OH)D, atra, dexamethasone, cytokines podocytes are terminally differentiated cells with little mitogenic potential, which does not allow for establishment of stable cell lines required for in vitro assays-the authors conditionally immortalized reporter podocytes REPON for sensitive, continuous monitoring of nephrin gene expression.
22 Vitamin D and nephrin expression. secreted alkaline phosphatase (SEAP)gene was fused to the promoter of the nephrin gene and introduced into conditionally immortalized podocytes. K Yamauchi et al.:kidney International (2006) 70,
23 Vitamin D and nephrin.. K Yamauchi et al.:kidney International (2006) 70,
24 Vitamin D and nephrin Immunohistochemistry A-Normal B-Nephrotic syndrome C-Low 22-oxacalcitriol D-High 22-oxacalcitriol E-low 1α,25(OH)2D3 F-High 1α,25(OH)2D3 Matsui et al. Nephrol Dial Transplant (2009) 24:
25 Vitamin D and podocin. Immunohistochemistry A-Normal B-Nephrotic syndrome C-Low 22-oxacalcitriol D-High 22-oxacalcitriol E-low 1α,25(OH)2D3 F-High 1α,25(OH)2D3 Matsui et al. Nephrol Dial Transplant (2009) 24:
26 Vitamin D and desmin Immunohistochemistry A-Normal B-Nephrotic syndrome C-Low 22-oxacalcitriol D-High 22-oxacalcitriol E-low 1α,25(OH)2D3 F-High 1α,25(OH)2D3 Matsui et al. Nephrol Dial Transplant (2009) 24:
27 Summary Vit D by altering the expression of nephrin podocin and desmin is thought to reduce protienuria in diseased kidneys.
28 Vit D and renoprotective effects Vit D and proteinuria. Vit D and RAS. Vit D and anti inflammatory effect. Vit D and immunomodulatory effects.
29 Vitamin D and Renin 184 healthy normotensive individuals. High sodium balance. No DM,CKD, CAD or active malignancy. 25(OH) VIT D and PRA was measured. RPF was calculated by PAH assays.
30
31 When adjusted for age race and BMI PRA was greater by0.17+/ ng/ml in Vit D deficiency when restricted to whites the levels were similar.
32 Angiotensin and renal Plasma flow
33 Vit D Status and incidence of hypertension Ann Intern Med Mar 2;152(5):307-14
34 Vit D Status and incidence of hypertension Ann Intern Med Mar 2;152(5):307-14
35 Vit D Status and incidence of hypertension Ann Intern Med Mar 2;152(5):307-14
36 Vit D supplementation and hypertension
37 Vit D supplementation and hypertension
38 Vit D supplementation and hypertension
39 Kidney international (2008) 73, If vit D provides reno protection, mice lacking VDR are more susceptible to hyperglycemia induced renal injury
40 Kidney Int Jan;73(2): Epub 2007 Oct 10.
41 Kidney international (2008) 73,
42 Kidney international (2008) 73,
43 Kidney international (2008) 73,
44 Kidney international (2008) 73,
45 Vit D and renoprotective effects Vit D and proteinuria. Vit D and RAS. Vit D and anti inflammatory effects. Vit D and immunomodulatory effects
46 Total of 174 CKD patients Checked both 25 (OH)D and 1,25 (OH)D levels Checked Urinary MCP (Macrophage chemoattractant protien) and index of chronic renal damage 111 patients had kidney biopsy (frozen available for PCR analysis) Kidney International (2008) 74,
47 Kidney International (2008) 74,
48 Kidney International (2008) 74,
49 MCP-macrophage chemoattractant protein 1,25(OH) VIT D 25(OH)VIT D Kidney International (2008) 74,
50 Kidney International (2008) 74,
51 Kidney International (2008) 74,
52 Vit D and renoprotective effects Vit D and proteinuria. Vit D and RAS. Vit D and anti inflammatory effect. Vit D and immunomodulatory effects.
53
54
55 Summary Down regulates T helper 1 cell assciated cytokines- IL-2 and IFN-Y. Up regulates T helper 2 cell associated cytokines- IL-4 and IL-5. Experiments in VDR KO mice produced high IL-2,IFN-Y and low IL4-IL-5. T helper 1 cells T helper 2 cells.
56 Overview of the potential renoprotective effects of active vitamin D in the damaged kidney Doorenbos, C. R. C. et al. (2009) Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism Nat. Rev. Nephrol. doi: /nrneph
57 Pleotropic effects of vitamin D Vit D and renoprotective and immunomodulatory effects. Vit D- Cardiometabolic actions.
58
59 Vit D and incidence of diabetes Ann Intern Med Mar 2;152(5):307-14
60 Vit D and incidence of diabetes Ann Intern Med Mar 2;152(5):307-14
61 Vit D and incidence of diabetes Ann Intern Med Mar 2;152(5):307-14
62 Vit D supplementation and diabetes Ann Intern Med Mar 2;152(5):307-14
63 Vit D supplementation and diabetes Ann Intern Med Mar 2;152(5):307-14
64 Vit D supplementation and diabetes Ann Intern Med Mar 2;152(5):307-14
65 Vit D supplementation and diabetes
66 VIT D status and incidence of CVD Ann Intern Med Mar 2;152(5):307-14
67 VIT D status and incidence of CVD Ann Intern Med Mar 2;152(5):307-14
68 VIT D status and incidence of CVD Ann Intern Med Mar 2;152(5):307-14
69 VIT D status and incidence of CVD Ann Intern Med Mar 2; (5):3
70 Vit D supplementation and CVD Ann Intern Med Mar 2;152(5):307-14
71 Vit D supplementation and CVD Ann Intern Med Mar 2;152(5):307-14
72 Vit D supplementation and CVD Ann Intern Med Mar 2;152(5):307-14
73 Conclusion There is a lot of promise regarding the beneficial effects of Vit D. Decent animal models showing the pleotrophic effects. More convincing data is required from human studies.
74 THANK YOU
02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis.
To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. Michael Shoemaker-Moyle, M.D. Assistant Professor of Clinical Medicine Objectives Review Vitamin D Physiology Review Current Replacement
More informationVitamin D: Is it a superhero??
Vitamin D: Is it a superhero?? Dr. Ashraf Abdel Basset Bakr Prof. of Pediatrics 1 2 History of vitamin D discovery Sources of vitamin D and its metabolism 13 Actions of vitamin D 4 Vitamin D deficiency
More informationSupplementary Information to Chapter 36
REVIEW ON VITAMIN-D NEW INSIGHTS Elmer Verner McCollum (1879-1967) was the first to discover the antirachitic vitamin which he named as vitamin D in the early part of 20th century (1919). He had earlier
More informationVitamin D and Inflammation
Vitamin D and Inflammation Susan Harris, D.Sc. Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University Boston, MA Vitamin D Liver 25(OH)D storage form nmol/l=ng/ml x 2.5 Renal 1,25(OH)
More informationVitamin D Deficiency. Decreases renal calcium excretion. Increases intestinal absorption Calcium. Increases bone resorption of calcium
Vitamin D Deficiency Deborah Gordish, MD Assistant Professor of Clinical Internal Medicine Lead Physician Lewis Center Primary Care Associate Division Director General Internal Medicine The Ohio State
More informationFOCUS ON CARDIOVASCULAR DISEASE
The Consequences of Vitamin D Deficiency: FOCUS ON CARDIOVASCULAR DISEASE Vitamin D deficiency is a global health problem. With all the medical advances of the century, vitamin D deficiency is still epidemic.
More informationEffective Treatment Strategies to Delay the Progression of Renal Disease in CKD
Effective Treatment Strategies to Delay the Progression of Renal Disease in CKD Csaba P Kovesdy, MD FASN Memphis VA Medical Center, Memphis TN University of Tennessee, Memphis TN Vitamin D Metabolic acidosis
More informationSLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota
SLOWING PROGRESSION OF KIDNEY DISEASE Mark Rosenberg MD University of Minnesota OUTLINE 1. Epidemiology of progression 2. Therapy to slow progression a. Blood Pressure control b. Renin-angiotensin-aldosterone
More informationKlotho: renal and extra-renal effects
Klotho: renal and extra-renal effects Juan F. Navarro-González, MD, PhD, FASN Nephrology Service and Research Division University Hospital Nuestra Señora de Candalaria Santa Cruz de Tenerife. Spain Klotho:
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationVitamin D: Conflict of Interest Statement Corporate. Outline 7/5/2016
Vitamin D: What s New and Not? Clifford J Rosen MD Maine Medical Center Research Institute rosenc@mmc.org Conflict of Interest Statement Corporate NO STOCKS or EQUITY Editor UpToDate, New England Journal
More informationShon E. Meek, M.D., Ph.D. Assistant Professor of Medicine
Shon E. Meek, M.D., Ph.D. Assistant Professor of Medicine meek.shon@mayo.edu 2016 MFMER 3561772-1 Update on Vitamin D Shon Meek MD, PhD 20 th Annual Endocrine Update January 30-Feb 3, 2017 Disclosure Relevant
More informationESPEN Congress Prague 2007
ESPEN Congress Prague 2007 Key papers in the field of nutrition Dietitian Geila S Rozen Key Papers in the field of Nutrition ESPEN 2007 Prague Geila S Rozen Clinical Nutrition Dep. Rambam health campus
More informationVitamin D Replacement ROCKY MOUNTAIN MEETING NOV 2013 BANFF W.COKE UNIVERSITY OF TORONTO
Vitamin D Replacement ROCKY MOUNTAIN MEETING NOV 2013 BANFF W.COKE UNIVERSITY OF TORONTO Disclosures: (Academic Mea Culpa) No financial conflicts I have no expertise re: Vitamin D. OBJECTIVES: 1) Review
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationrenoprotection therapy goals 208, 209
Subject Index Aldosterone, plasminogen activator inhibitor-1 induction 163, 164, 168 Aminopeptidases angiotensin II processing 64 66, 214 diabetic expression 214, 215 Angiotensin I intrarenal compartmentalization
More informationUric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George
Uric acid and CKD Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George Hospital @Badves Case Mr J, 52 Male, referred in June 2015 DM type 2 (4 years), HTN, diabetic retinopathy, diabetic
More informationChronic Kidney Disease
Chronic Kidney Disease Presence of kidney damage or decreased kidney function for three or more months, - necessary to distinguish CKD from acute kidney disease. Ascertained either by kidney biopsy or
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationFeinberg School of Medicine Chicago IL Division of Nephrology and Hypertension
Feinberg School of Medicine Chicago IL Division of Nephrology and Hypertension Daniel Batlle MD Earle, del Greco Levin Professor of Medicine Division of Nephrology and Hypertension Northwestern University
More informationAGING KIDNEY IN HIV DISEASE
AGING KIDNEY IN HIV DISEASE Michael G. Shlipak, MD, MPH Professor of Medicine, Epidemiology and Biostatistics, UCSF Chief, General Internal Medicine, San Francisco VA Medical Center Kidney, Aging and HIV
More informationAre we really all vitamin D deficient?
Are we really all vitamin D deficient? Anders H Berg, MD, PhD Assistant Professor of Pathology Harvard Medical School Assistant Director of Clinical Chemistry Beth Israel Deaconess Medical Center Grant
More informationMohammad Husain Department of Biotechnology, Jamia Millia Islamia New Delhi
Role of Vitamin D receptor (VDR) in HIV induced tubular injury Mohammad Husain Department of Biotechnology, Jamia Millia Islamia New Delhi 07/10/2015 INTRODUCTION Vitamin D is technically not a Vitamin;
More informationProf. Andrzej Wiecek Department of Nephrology, Endocrinology and Metabolic Diseases Medical University of Silesia Katowice, Poland.
What could be the role of renal denervation in chronic kidney disease? Andrzej Wiecek, Katowice, Poland Chairs: Peter J. Blankestijn, Utrecht, The Netherlands Jonathan Moss, Glasgow, UK Prof. Andrzej Wiecek
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A A Diabetes Outcome Progression Trial (ADOPT), 194 Adaptive immunity, 129 131 ADOPT (A Diabetes Outcome Progression Trial), 194 Aging, vitamin
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationJ.Bacchetta has documented that she has received grants for research activities from Amgen, Crinex, Sandoz.
J.Bacchetta has documented that she has received grants for research activities from Amgen, Crinex, Sandoz. Epidemiological, immune and metabolic aspects of vitamin D in CKD Justine Bacchetta, MD, PhD
More informationVITAMIN D. Christina Nieuwoudt RD(SA) CCSSA/SASPEN 2018
VITAMIN D Christina Nieuwoudt RD(SA) CCSSA/SASPEN 2018 1 OBJECTIVES Why is it in the spotlight? Vit D and acute illness If it has a role how much should we give? Future 2 Why is it in the spotlight? FUNCTIONS
More informationDiabetes and Kidney Disease. Kris Bentley Renal Nurse practitioner 2018
Diabetes and Kidney Disease Kris Bentley Renal Nurse practitioner 2018 Aims Develop an understanding of Chronic Kidney Disease Understand how diabetes impacts on your kidneys Be able to recognise the risk
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Protein Restriction to prevent the progression of diabetic nephropathy GUIDELINES
Protein Restriction to prevent the progression of diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. A small volume of evidence suggests
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationProtocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.
Protocol GTC-68-208: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. These results are supplied for informational purposes only.
More informationInterventions to reduce progression of CKD what is the evidence? John Feehally
Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think
More informationTHE ROLE OF URIC ACID IN THE PROGRESSION OF CKD Mehmet Kanbay, Istanbul, Turkey
THE ROLE OF URIC ACID IN THE PROGRESSION OF CKD Mehmet Kanbay, Istanbul, Turkey Chairs: Gerjan Navis, Groningen, The Netherlands Kamil Serdengecti, Istanbul, Turkey Dr. M. Kanbay Division of Nephrology
More informationVitamin D and Calcium Therapy: how much is enough
Vitamin D and Calcium Therapy: how much is enough Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco DISCLOSURE Nothing to disclose 1 RECOMMENDATIONS
More informationThe Endocrine Society Guidelines
Vitamin D and Calcium Therapy: how much is enough DISCLOSURE Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco Nothing to disclose RECOMMENDATIONS
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Prevalence and Pattern of Mineral Bone Disorder in Chronic Kidney Disease Patients Using Serum
More informationFigure 1 LVH: Allowed Cost by Claim Volume (Data generated from a Populytics analysis).
Chronic Kidney Disease (CKD): The New Silent Killer Nelson Kopyt D.O. Chief of Nephrology, LVH Valley Kidney Specialists For the past several decades, the health care needs of Americans have shifted from
More informationKerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009
Kerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009 DR. KERRY COOPER IS ON THE SPEAKER BUREAU OF AMGEN, ABBOTT, GENZYME, SHIRE, AND BMS DR. COOPER IS ALSO INVOLVED IN CLINICAL
More informationIpovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale. Maurizio Gallieni Università degli Studi di Milano
Ipovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale Maurizio Gallieni Università degli Studi di Milano G Ital Nefrol 2018 - ISSN 1724-5990 Nutrients 2017, 9, 328 Vitamin D deficiency (
More informationOutline. The Role of Vitamin D in CKD. Essential Role of Vitamin D. Mechanism of Action of Vit D. Mechanism of Action of Vit D 7/16/2010
Outline The Role of Vitamin D in CKD Priscilla How, Pharm.D., BCPS Assistant Professor National University of Singapore Principal Clinical Pharmacist National University Hospital (Pharmacy and Nephrology,
More informationVitamin D. Vitamin functioning as hormone. Todd A Fearer, MD FACP
Vitamin D Vitamin functioning as hormone Todd A Fearer, MD FACP Vitamin overview Vitamins are organic compounds that are essential in small amounts for normal metabolism They are different from minerals
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationSecondary hyperparathyroidism an Update on Pathophysiology and Treatment
Secondary hyperparathyroidism an Update on Pathophysiology and Treatment Klaus Olgaard Copenhagen Budapest Nephrology School August 2007 HPT IN CRF Renal mass Ca 2+ 1,25(OH) 2 D 3 CaR Hyperparathyroidism
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationManagement of early chronic kidney disease
Management of early chronic kidney disease GREENLANE SUMMER GP SYMPOSIUM 2018 Jonathan Hsiao Renal and General Physician Introduction A growing public health problem in NZ and throughout the world. Unknown
More informationCardiovascular Pharmacotherapy in Special Population: Cardio-Nephrology
49 th Annual Scientific Meeting The Heart Association of Thailand under the Royal Patronage of H.M. the King Cardiology on the move 24-25 March 2017 @Sheraton, HuaHin Cardiovascular Pharmacotherapy in
More informationVitamin D in Cattle: Calcium and Beyond. Corwin D. Nelson, Ph.D. Assistant Professor of Physiology Department of Animal Sciences
OH HO OH Vitamin D in Cattle: Calcium and Beyond Corwin D. Nelson, Ph.D. Assistant Professor of Physiology Department of Animal Sciences Seminar Outline 1. Basics of vitamin D metabolism and genomic actions
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationProceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009
www.ivis.org Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009 São Paulo, Brazil - 2009 Next WSAVA Congress : Reprinted in IVIS with the permission of the Congress Organizers PROTEINURIA
More informationIS VITAMIN D IMPORTANT IN THE MANAGEMENT OF TUBERCULOSIS?
IS VITAMIN D IMPORTANT IN THE MANAGEMENT OF TUBERCULOSIS? Dr Heather Milburn Consultant Respiratory Physician Guy s & St Thomas NHS Foundation Trust READER IN Respiratory Medicine KING S College London
More informationStages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
More informationRENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2
Treatment of Diabetic Nephropathy and Proteinuria Background End stage renal disease is a major cause of death and disability among diabetics BP reduction is important to slow the progression of diabetic
More informationVitamin D & Cardiovascular Disease
Vitamin D & Cardiovascular Disease Disclosures None Vitamin D Objectives: Discuss the basics of vitamin D metabolism Discuss the role of vitamin D deficiency in the development of coronary disease Review
More informationMANAGEMENT CALL TO DISCUSS LONGER-TERM IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE
MANAGEMENT CALL TO DISCUSS LONGER-TERM IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE Introduction Substantial body of prior CKD clinical data characterizes Bard s unique profile Bard has demonstrated
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meeting 12 th September 2017 - Sheffield Prof Sunil Bhandari Consultant
More informationDiabetic Nephropathy 2009
Diabetic Nephropathy 2009 Michael T McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetic Nephropathy Clinical Stages Hyperfunction
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationAlan S. Peterson, M.D. Associate Director, Family & Community Medicine Walter L. Aument Family Health Center
Alan S. Peterson, M.D. Associate Director, Family & Community Medicine Walter L. Aument Family Health Center As readers of this Journal may recall, the Winter 2006-07 issue of JLGH (Volume 1, No. 3) was
More informationJOSHUA K. KAYIMA INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY
INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY JOSHUA K. KAYIMA ASSOCIATE PROFESSOR DEPT. OF CLINICAL MEDICINE AND THERAPEUTICS UNIVERSITY OF NAIROBI Introduction According to
More informationCardiovascular Mortality: General Population vs ESRD Dialysis Patients
Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP
More informationEmerging Areas Relating Vitamin D to Health
ILSI SEA Region Vit D Conference, Australia, June 2012 (www.ilsi.org/sea Region) Emerging Areas Relating Vitamin D to Health Peter R Ebeling MD FRACP NorthWest Academic Centre and Dept Endocrinology The
More informationPrognosis in CKD Can we do anything about it? Rodney D Gilbert
Prognosis in CKD Can we do anything about it? Rodney D Gilbert A diagnosis of end stage renal failure implies what degree of loss of life expectancy? A. 10% B. 20% C. 30% D. 40% E. 50% F. 60% 38% 22% 16%
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Cheng MH, Fan U, Grewal N, et al. Acquired autoimmune polyglandular
More information23-Jun-15. Albuminuria Renal and Cardiovascular Consequences A history of progress since ,490,000. Kidney Center, UMC Groningen
Kidney function (egfr in ml/min) Albuminuria (mg/hr) Incidentie ESRD (%) 3-Jun- Number of patients worldwide that receives kidney replacement therapy Albuminuria Renal and Cardiovascular Consequences A
More informationVitamin D receptor gene polymorphism and serum levels of Fetuin-A, Vitamin D and ipth in the hemodialysis patients
In The Name of GOD Vitamin D receptor gene polymorphism and serum levels of Fetuin-A, Vitamin D and ipth in the hemodialysis patients Authors & Affiliations: 1-jamal hallajzadeh; Maraghe University of
More informationCardiovascular Implications of Proteinuria
Cardiovascular Implications of Proteinuria B. S. Kasinath, MD University of Texas Health Science Center South Texas Veterans Health Care System San Antonio Objectives Mechanisms of albumin handling by
More informationManaging patients with renal disease
Managing patients with renal disease Hiddo Lambers Heerspink, MD University Medical Centre Groningen, The Netherlands Asian Cardio Diabetes Forum April 23 24, 216 Kuala Lumpur, Malaysia Prevalent cases,
More informationVitamin D Hormone Du Jour
Vitamin D Hormone Du Jour J R Minkoff MD, FACP Endocrinology Clinical Professor of Family and Community Medicine UCSF Why Is Vitamin D Important? Musculo-skeletal effects Possible other effects Immunomodulatory
More informationSeung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine
Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline
More informationThe discovery of Vitamin D and the elimination of rickets has been considered as one of Medicine s Greatest Achievements.
The discovery of Vitamin D and the elimination of rickets has been considered as one of Medicine s Greatest Achievements. SIR EDWARD MELLANBY 1 8 8 4-1 9 5 5 A D I E T C H A R A C T E R I S T I C O F S
More informationVITAMIN D IN HEALTH & DISEASE. Boyd C.Hoddinott B Sc, MD, MPH Logan County Health Commissioner
VITAMIN D IN HEALTH & DISEASE Boyd C.Hoddinott B Sc, MD, MPH Logan County Health Commissioner Summary Foods in North America were fortified with vitamin D to reduce the occurrence of rickets. This appeared
More informationFigure S1. Reduction in glomerular mir-146a levels correlate with progression to higher albuminuria in diabetic patients.
Supplementary Materials Supplementary Figures Figure S1. Reduction in glomerular mir-146a levels correlate with progression to higher albuminuria in diabetic patients. Figure S2. Expression level of podocyte
More informationClinical Pearls in Renal Medicine
Clinical Pearls in Renal Medicine Joel A. Gordon MD Professor of Medicine Nephrology Division Staff Physician Kidney Disease and Blood Pressure Clinic Disclosures None of my financial holdings will have
More informationCardiovascular Protection and the RAS
Cardiovascular Protection and the RAS Katalin Kauser, MD, PhD, DSc Senior Associate Director, Boehringer Ingelheim Pharmaceutical Inc. Micardis Product Pipeline Scientific Support Ridgefield, CT, USA Cardiovascular
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationWORKSHOP #6: LA DISFUNZIONE VENTRICOLARE OCCULTA E NON: - Nella Patologia renale. Luigi Tarantini Osp. San Martino - (Belluno)
WORKSHOP #6: LA DISFUNZIONE VENTRICOLARE OCCULTA E NON: - Nella Patologia renale Luigi Tarantini Osp. San Martino - (Belluno) Il paziente con Malattia Renale Cronica è il paziente ad alto rischio CV (1)
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationVitamin D and Cardiovascular Disease
Vitamin D and Cardiovascular Disease Carrie W. Nemerovski, Pharm.D., Michael P. Dorsch, Pharm.D., Robert U. Simpson, Ph.D., Henry G. Bone, M.D., Keith D. Aaronson, M.D., and Barry E. Bleske, Pharm.D.,
More informationOffice Management of Reduced GFR Practical advice for the management of CKD
Office Management of Reduced GFR Practical advice for the management of CKD CKD Online Education CME for Primary Care April 27, 2016 Monica Beaulieu, MD FRCPC MHA CHAIR PROVINCIAL KIDNEY CARE COMMITTEE
More informationDisclosure 7/2/2018. Consultant : Ultragenyx, Alexion, Ferrings. Research grant support: Ultragenyx, Shire, Amgen. Clinical Trial : Ultragynyx, Amgen
Pisit (Duke) Pitukcheewanont, MD, FAAP Clinical Director, Pediatric Bone Program, Center for Diabetes, Endocrinology & Metabolism Children s Hospital Los Angeles Professor of Clinical Pediatrics The Keck
More informationQamar J. Khan Bruce F. Kimler Pavan S. Reddy Priyanka Sharma Jennifer R. Klemp Carol J. Fabian
The VITAL trial Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms and fatigue in women with breast cancer starting adjuvant letrozole. Qamar J. Khan Bruce F. Kimler Pavan
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationProf. Armando Torres Nephrology Section Hospital Universitario de Canarias University of La Laguna Tenerife, Canary Islands, Spain.
Does RAS blockade improve outcomes after kidney transplantation? Armando Torres, La Laguna, Spain Chairs: Hans De Fijter, Leiden, The Netherlands Armando Torres, La Laguna, Spain Prof. Armando Torres Nephrology
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationComparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients. Int.J.Curr.Res.Aca.Rev.2016; 4(11):
Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients Seyed Seifollah Beladi Mousavi 1, Arman Shahriari 2 and Fatemeh Roumi 3 * 1 Department of Nephrology,
More informationThe Association of Vitamin D Deficiency and Insufficiency with Diabetic Nephropathy: Implications for Health Disparities
The Association of Vitamin D Deficiency and Insufficiency with Diabetic Nephropathy: Implications for Health Disparities Vanessa A. Diaz, MD, MS, Arch G. Mainous III, PhD, Peter J. Carek, MD, MS, Andrea
More informationPROs for Drug Development. Melanie Blank, MD
PROs for Drug Development in Chronic Kidney Disease Melanie Blank, MD Disclaimer The views expressed here represent my opinions and do not necessarily represent the views of the FDA. Overview Stagnation
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationACEIs / ARBs NDHP dihydropyridine ( DHP ) ACEIs ARBs ACEIs ARBs NDHP. ( GFR ) 60 ml/min/1.73m ( chronic kidney disease, CKD )
005 16 175-180 1 1 ( chronic kidney disease, CKD ) 003 ( end-stage renal disease, ESRD ) Angiotensin-converting enzyme inhibitors ( ) angiotensin receptor blockers ( ) nondihydropyridine ( NDHP ) / NDHP
More informationBenefits of Vitamin D for Cancer and Pregnancy/Birth Outcomes. William B. Grant, PhD Sunlight, Nutrition and Health Research Center, San Francisco
Benefits of Vitamin D for Cancer and Pregnancy/Birth Outcomes William B. Grant, PhD Sunlight, Nutrition and Health Research Center, San Francisco Disclosure I receive funding from Bio Tech Pharmacal, Inc.
More informationKDIGO Controversies Conference on Management of Patients with Diabetes and Chronic Kidney Disease
KDIGO Controversies Conference on Management of Patients with Diabetes and Chronic Kidney Disease February 5-8, 2015 Vancouver, Canada Kidney Disease: Improving Global Outcomes (KDIGO) is an international
More informationAttivazione selettiva dei VDR nella CKD-MBD: dalla conservativa alla dialisi
Attivazione selettiva dei VDR nella CKD-MBD: dalla conservativa alla dialisi Mario Cozzolino, MD, PhD, FERA Dipartimento di Scienze della Salute Università di Milano UO Nefrologia e Dialisi Laboratorio
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationPOSITION STATEMENT Vit D
POSITION STATEMENT Vit D APPROVED BY THE AUSTRALIAN AND NEW ZEALAND BONE AND MINERAL SOCIETY, RISKS AND BENEFITS OF SUN EXPOSURE POSITION STATEMENT Summary statement A balance is required between avoiding
More informationManagement of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA
Management of New-Onset Proteinuria in the Ambulatory Care Setting Akinlolu Ojo, MD, PhD, MBA Urine dipstick results Negative Trace between 15 and 30 mg/dl 1+ between 30 and 100 mg/dl 2+ between 100 and
More informationAldosterone synthase inhibitors. John McMurray BHF Cardiovascular Research Centre University of Glasgow
Aldosterone synthase inhibitors John McMurray BHF Cardiovascular Research Centre University of Glasgow Inhibition of aldosterone synthesis is hypothesized to be of benefit to patients with cardiovascular
More information